Bartlett, J. G. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin. Infect. Dis. 18 (Suppl. 4), S265–S272 (1994).
Exceptional overview of historical studies and the development of recognition of C. difficile as a human pathogen.
Kim, J. et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001–2006. Pediatrics 122, 1266–1270 (2008).
Rouphael, N. G. et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am. J. Obstet. Gynecol. 198, 635.e1–e6 (2008).
Pepin, J. et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can. Med. Assoc. J. 171, 466–472 (2004).
Loo, V. G. et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442–2449 (2005).
Key early study that highlights the transmission, potential risk factors for, and impact of, a new virulent C. difficile clone.
Labbe, A. C. et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother. 52, 3180–3187 (2008).
Dallal, R. M. et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235, 363–372 (2002).
First documentation of the high severity and mortality of CDI, which was subsequently shown to be caused by the C. difficile BI/NAP1/027 strain.
Kuijper, E. J. et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 13, pii: 18942 (2008).
Kuijper, E. J., Coignard, B. & Tull, P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12 (Suppl. 6), 2–18 (2006).
Burckhardt, F., Friedrich, A., Beier, D. & Eckmanns, T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg. Infect. Dis. 14, 691–692 (2008).
Soler, P., Nogareda, F. & Cano, R. Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997–2005. Infect. Control Hosp. Epidemiol. 29, 887–889 (2008).
Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online], (2008).
McDonald, L. C. et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433–2441 (2005).
First report of the toxin variant C. difficile BI/NAP1/027 in the United States.
Muto, C. A. et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273–280 (2005).
Hubert, B. et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin. Infect. Dis. 44, 238–244 (2007).
Killgore, G. et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J. Clin. Microbiol. 46, 431–437 (2008).
Updated comparison of typing techniques for C. difficile.
Fawley, W. N. et al. Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains. J. Clin. Microbiol. 46, 954–960 (2008).
Borgmann, S. et al. Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Euro Surveill. 13, pii: 19057 (2008).
Goorhuis, A. et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47, 1162–1170 (2008).
Rupnik, M., Widmer, A., Zimmermann, O., Eckert, C. & Barbut, F. Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J. Clin. Microbiol. 46, 2146 (2008).
Hirschhorn, L. R., Trnka, Y., Onderdonk, A., Lee, M. L. & Platt, R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J. Infect. Dis. 169, 127–133 (1994).
Chernak, E. et al. Severe Clostridium difficile–associated disease in populations previously at low risk — four states. Morb. Mortal. Wkly Rep. 54, 1201–1205 (2005).
Centers for Disease Control and Prevention (CDC). Surveillance for community-associated Clostridium difficile--Connecticut, 2006. Morb. Mortal. Wkly Rep. 57, 340–343 (2008).
Wilcox, M. H., Mooney, L., Bendall, R., Settle, C. D. & Fawley, W. N. A case-control study of community-associated Clostridium difficile infection. J. Antimicrob. Chemother. 62, 388–396 (2008).
Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
al Saif, N. & Brazier, J. S. The distribution of Clostridium difficile in the environment of South Wales. J. Med. Microbiol. 45, 133–137 (1996).
Documentation of the high level of environmental contamination by C. difficile.
Rodriguez-Palacios, A., Staempfli, H. R., Duffield, T. & Weese, J. S. Clostridium difficile in retail ground meat, Canada. Emerg. Infect. Dis. 13, 485–487 (2007).
Songer, J. et al. Clostridium difficile in retail meat products, USA, 2007. Emerg. Infect. Dis. 15, 819–821 (2009).
Jhung, M. A. et al. Toxinotype V Clostridium difficile in humans and food animals. Emerg. Infect. Dis. 14, 1039–1045 (2008).
Rupnik, M. Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin. Microbiol. Infect. 13, 457–459 (2007).
Songer, G. J. & Anderson, M. A. Clostridium difficile: an important pathogen of food animals. Anaerobe 12, 1–4 (2006).
Rodruiges-Palacios, A. et al. Clostridium difficile PCR ribotypes in calves, Canada. Emerg. Infect. Dis. 12, 1730–1736 (2006).
Keel, K. & Songer, J. G. The comparative pathology of Clostridium difficile-associated disease. Vet. Pathol. 43, 225–240 (2006).
Keel, K., Brazier, J. S., Post, K. W., Weese, S. & Songer, J. G. Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J. Clin. Microbiol. 45, 1963–1964 (2007).
Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).
Chang, J. Y. et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435–438 (2008).
Confirmation of the suspected alteration of the normal bacterial flora in patients with recurrent CDI.
Merrigan, M. M., Sambol, S. P., Johnson, S. & Gerding, D. N. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188, 1922–1927 (2003).
Merrigan, M., Sambol, S., Johnson, S. & Gerding, D. Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe 9, 91–95 (2003).
Johnson, S. et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341, 1645–1651 (1999).
Baines, S. D. et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62, 1046–1052 (2008).
Evidence for the emergence and local spread of reduced susceptibility of C. difficile to metronidazole, one of only two main options for the treatment of CDI.
Peláez, T. et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46, 3028–3032 (2008).
O'Connor, J. R. et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52, 2813–2817 (2008).
Bartlett, J. G. & Gerding, D. N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 46 (Suppl. 1), 12–18 (2008).
Johansen, A., Vasishta, S., Edison, P. & Hosein, I. Clostridium difficile associated diarrhoea: how good are nurses at identifying the disease? Age Ageing 31, 487–488 (2002).
Burdette, S. D. & Bernstein, J. M. Does the nose know? The odiferous diagnosis of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 44, 1142 (2007).
Wilcox, M. H. Diagnosis of Clostridium difficile-associated diarrhea and odor. Clin. Infect. Dis. 45, 1110 (2007).
Planche, T. et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect. Dis. 8, 777–784 (2008).
Summary data showing why there are concerns about the accuracy and poor predictive value of toxin detection kits.
Sloan, L. M., Duresko, B. J., Gustafson, D. R. & Rosenblatt, J. E. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 46, 1996–2001 (2008).
Riggs, M. M. et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis. 45, 992–998 (2007).
Ticehurst, J. R. et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J. Clin. Microbiol. 44, 1145–1149 (2006).
Silva, J. Jr et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am. J. Med. 71, 815–822 (1981).
Teasley, D. G. et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2, 1043–1046 (1983).
Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. & Davis, M. B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45, 302–307 (2007).
Reported a prospective, randomized, stratified, blinded trial that revealed the superiority of vancomycin versus metronidazole for the treatment of severe CDI.
Johnson, S., Adelmann, A., Clabots, C. R., Peterson, L. R. & Gerding, D. N. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 159, 340–343 (1989).
O'Neill, G. L., Beaman, M. H. & Riley, T. V. Relapse versus reinfection with Clostridium difficile. Epidemiol. Infect. 107, 627–635 (1991).
Aas, J., Gessert, C. E. & Bakken, J. S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36, 580–585 (2003).
Lamontagne, F. et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann. Surg. 245, 267–272 (2007).
Dial, S., Kezouh, A., Dascal, A., Barkun, A. & Suissa, S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. Can. Med. Assoc. J. 179, 767–772 (2008).
Gaynes, R. et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis. 38, 640–645 (2004).
Pepin, J. et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254–1260 (2005).
Dial, S., Alrasadi, K., Manoukian, C., Huang, A. & Menzies, D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can. Med. Assoc. J. 171, 33–38 (2004).
Kyne, L., Warny, M., Qamar, A. & Kelly, C. P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342, 390–397 (2000).
Kyne, L., Warny, M., Qamar, A. & Kelly, C. P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189–193 (2001).
Hu, M. Y. et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136, 1206–1214 (2009).
Sebaihia, M. et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nature Genet. 38, 779–786 (2006).
Thelestam, M. & Chaves-Olarte, E. Cytotoxic effects of the Clostridium difficile toxins. Curr. Top. Microbiol. Immunol. 250, 85–96 (2000).
Rupnik, M. & Just, I. in The Comprehensive Sourcebook of Bacterial Protein Toxins 3rd edn (eds Alouf, J. A. & Popoff, M. R.) 409–429 (Academic Press, Burlington, Massachusetts, USA, 2006).
Jank, T., Giesemann, T. & Aktories, K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17, 15R–22R (2007).
Overview of our current knowledge of the structural basis of toxin functions.
Riegler, M. et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J. Clin. Invest. 95, 2004–2011 (1995).
Pothoulakis, C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. NY Acad. Sci. 915, 347–356 (2000).
Hamm, E., Voth, D. E. & Ballard, J. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl Acad. Sci. USA 103, 14176–14181 (2006).
Lyerly, D. M., Saum, K. E., MacDonald, D. K. & Wilkins, T. D. Effects of Clostridium difficile given intragastrically to animals. Infect. Immun. 47, 349–352 (1985).
Heap, J. T., Pennington, O. J., Cartman, S. T., Carter, G. P. & Minton, N. P. The ClosTron: a universal gene knock-out system for the genus Clostridium. J. Microbiol. Methods 70, 452–464 (2007).
Lyras, D. et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176–1179 (2009).
von Eichel-Streiber, C., Boquet, P., Sauerborn, M. & Thelestam, M. Large clostridial cytotoxins — a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol. 4, 375–382 (1996).
Amimoto, K., Taichi, N., Eiji, O. & Mitsugu, S. A novel toxin homologous to large clostridial catotoxins found in culture supernatant of Clostridium perfringens type C. Microbiology 153, 1198–1206 (2007).
Just, I. et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375, 500–503 (1995).
Na, X., Kim, H., Moyer, M. P., Pohoulakis, C. & LaMont, T. J. gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect. Immun. 76, 2862–2871 (2008).
Reineke, J. et al. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446, 415–419 (2007).
First description of self-cleavage of bacterial toxins during internalization in the host cell.
Egerer, M., Giesemann, T., Jank, T., Satchell, K. J. & Aktories, K. Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J. Biol. Chem. 282, 25314–25321 (2007).
Mani, N. & Dupuy, B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl Acad. Sci. USA 98, 5844–5849 (2001).
Matamouros, S., England, P. & Dupuy, B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 64, 1274–1288 (2007).
Tan, K. S., Wee, B. Y. & Song, K. P. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J. Med. Microbiol. 50, 613–619 (2001).
Braun, V., Hundsberger, T., Leukel, P., Sauerborn, M. & Eichel-Streiber, C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181, 29–38 (1996).
Description of the chromosomal element that encodes TcdA and TcdB.
Rupnik, M. et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J. Med. Microbiol. 54, 113–117 (2005).
Rupnik, M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol. Rev. 2, 541–555 (2008).
Hundsberger, T. et al. Transcription analysis of the genes tcdA–E of the pathogenicity locus of Clostridium difficile. Eur. J. Biochem. 244, 735–742 (1997).
Dupuy, B., Govind, R., Antunes, A. & Matamouros, S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J. Med. Microbiol. 57, 685–689 (2008).
Freeman, J., Baines, S. D. & Wilcox, M. H. Comparison of the efficacy of ramoplanin vs vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J. Antimicrob. Chemother. 56, 717–725 (2005).
Saxton, K., Baines, S. D., Freeman, J., O'Connor, R. & Wilcox, M. H. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob. Agents Chemother. 53, 412–420 (2009).
Dineen, S. S., Villapakkam, A. C., Nordman, J. T. & Sonenshein, A. L. Repression of Clostridium difficile toxin gene expression by CodY. Mol. Microbiol. 66, 206–219 (2007).
Stubbs, S. et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol. Lett. 186, 307–312 (2000).
Carter, G. P. et al. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J. Bacteriol. 189, 7290–7301 (2007).
Perelle, S., Gibert, M., Bourlioux, P., Corthier, G. & Popoff, M. R. Production of a complete binary toxin (actin-specific ADP-ribosyltranferase) by Clostridium difficile CD196. Infect. Immun. 65, 1402–1407 (1997).
Geric, B. et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 193, 1143–1150 (2006).
Calabi, E. & Fairweather, N. Patterns of sequence conservation in the S-layer proteins and related sequences in Clostridium difficile. J. Bacteriol. 184, 33886–33897 (2002).
Drudy, D. et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol. Med. Microbiol. 41, 237–242 (2004).
Wright, A. et al. Proteomic analysis of cell surface proteins from Clostridium difficile. Proteomics 5, 2443–2452 (2005).
Péchiné, S., Janoir, C. & Collignon, A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J. Clin. Microbiol. 43, 5018–5025 (2005).
Ausiello, C. M. et al. Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect. 8, 2640–2646 (2006).
Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Fawley, W. N. et al. Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect. Control Hosp. Epidemiol. 28, 920–925 (2007).
Quantification of the activity of detergents and disinfectants against C. difficile and the potential for some of these products to promote sporulation.
Hellickson, L. A. & Owens, K. L. Cross-contamination of Clostridium difficile spores on bed linen during laundering. Am. J. Infect. Control 35, E32–E33 (2007).
Wilcox, M. H. & Fawley, W. N. Hospital disinfectants and spore formation by Clostridium difficile. Lancet 356, 1324 (2000).
Baines, S. D., O'Connor, R., Saxton, K., Freeman, J. & Wilcox, M. H. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 63, 520–525 (2009).
Baines, S. D., O'Connor, R., Saxton, K., Freeman, J. & Wilcox, M. H. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J. Antimicrob. Chemother. 62, 1078–1085 (2008).
Johnson, S. et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am. J. Med. 88, 137–140 (1990).
Brooks, S. et al. Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect. Control Hosp. Epidemiol. 19, 333–336 (1998).
Jernigan, J. A., Siegman-Igra, Y., Guerrant, R. C. & Farr, B. M. A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect. Control Hosp. Epidemiol. 19, 494–499 (1998).
Samore, M. H., Venkataraman, L., DeGirolami, P. C., Arbeit, R. D. & Karchmer, A. W. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am. J. Med. 100, 32–40 (1996).
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. & Stamm, W. E. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320, 204–210 (1989).
Mayfield, J. L., Leet, T., Miller, J. & Mundy, L. M. Environmental control to reduce transmission of Clostridium difficile. Clin. Infect. Dis. 31, 995–1000 (2000).
Wilcox, M. H. et al. Comparison of effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J. Hosp. Infect. 54, 109–114 (2003).
Wilcox, M. H. et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 54, 168–172 (2004).
Davey, P. et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev. 19, CD003543 (2005).
Davey, P. et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis. 12, 211–216 (2006).
Valiquette, L., Cossette, B., Garant, M. P., Diab, H. & Pepin, J. Impact of a reduction in the use of high risk antibiotics on the course of an epidemic of Clostridium difficile associated disease caused by the hypervirulent NAP1/027 strain. Clin. Infect. Dis. 45, S112–S121 (2007).
Useful assessment of the major changes to antimicrobial prescribing that were implemented as part of the control of a large outbreak of CDI caused predominantly by a new virulent C. difficile clone.
Muto, C. A. et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a University hospital using a comprehensive 'bundle' approach. Clin. Infect. Dis. 45, 1266–1273 (2007).
Dendukuri, N., Costa, V., McGregor, M. & Brophy, J. M. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Can. Med. Assoc. J. 173, 167–170 (2005); erratum 173, 345 (2005).
Dendukuri, N. & Brophy, J. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am. J. Gastroenterol. 102, 201 (2007); author reply 102, 202–204 (2007).
Lewis, S. Response to the article: McFarland, L. V. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101, 812–822 (2006). Am. J. Gastroenterol. 102, 201–202 (2007).
Rupnik, M., Avesani, V., Janc, M., Eichel-Streiber, C. & Delmee, M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 36, 2240–2247 (1998).
Curry, S. R. et al. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J. Clin. Microbiol. 45, 215–221 (2007).
Shim, J. K., Johnson, S., Samore, M. H., Bliss, D. Z. & Gerding, D. N. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351, 633–636 (1998).